Novo's semaglutide superior to Bydureon

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said once-weekly subcutaneous semaglutide ( NN9535) was superior to once-weekly Bydureon exenatide in reducing baseline HbA1c and body weight in the SUSTAIN 3 study to treat Type II diabetes. Both treatments are glucagon-like peptide (GLP-1) receptor agonists; AstraZeneca plc (LSE:AZN; NYSE:AZN) markets Bydureon to treat Type II diabetes.

In the 813-patient trial, 1 mg semaglutide reduced HbA1c from baseline by 1.5%, compared to 0.9% with 2 mg Bydureon treatment, achieving the study's primary objective. Weight change from baseline with semaglutide was -5.6 kg vs. -1.8 kg for Bydureon, a secondary endpoint. ...